-
2024-515706-77-00
5
2025-05-08
Moderate to Severe Plaque Psoriasis
-
2024-517062-42-00
5
2025-05-02
melanoma, cutaneous malignant
-
2024-515245-42-00
3
2025-04-24
Ewing Sarcoma
-
2024-512659-19-00
10
2025-03-31
Advanced Melanoma
-
2024-512733-32-00
5
2025-03-31
Acute Myeloid Leukemia (AML)
-
2024-513018-36-00
5
2025-03-06
Lung Diseases, Interstitial
-
2024-512484-31-00
4
2025-02-28
FGFR2b-positive, advanced or metastatic adenocarcinoma of the stomach
-
2023-506605-19-00
5
2025-02-11
Bipolar depression
-
2024-511879-16-00
5
2024-12-12
Prurigo Nodularis
-
2023-503630-44-00
10
2024-11-20
Treatment of moderate-to-severe Atopic dermatitis
-
2024-511404-17-00
5
2024-10-07
Unresectable or metastatic NRAS mutant cutaneous melanoma
-
2023-507129-40-00
4
2024-08-06
interstitial lung disease secondary to systemic sclerosis (SSc-ILD)
-
2023-506602-39-00
6
2024-08-01
schizophrenia, schizoaffective disorder, schizophrenifom disorder
-
2023-505303-23-00
5
2024-07-26
Obesity
-
2023-503699-25-00
5
2024-07-15
Progressive Pulmonary Fibrosis
-
2023-503697-21-01
5
2024-06-24
Idiopathic pulmonary fibrosis
-
2023-506267-33-00
3
2024-05-29
Non-Hodgkin Lymphoid Malignancies
-
2022-502405-15-01
4
2024-04-08
Mantle Cell Lymphoma (MCL)
-
2023-507402-13-00
5
2024-04-03
Multiple myeloma
-
2023-507039-39-00
5
2024-03-22
Moderate to Severe Plaque Psoriasis
-
2022-501606-35-01
11
2024-02-21
Platinum-sensitive epithelial ovarian, fallopian tube, or primary
peri
-
2022-501157-36-00
6
2024-02-07
Critically ill patients who are dependent on high level medical care i
-
2023-505604-32-00
5
2024-01-24
Non small cell lung cancer (NSCLC)
-
2022-502660-20-00
5
2024-01-23
Follicular lymphoma